A federal judge in Texas issued a ruling Friday to revoke the Food and Drug Administration’s nearly 23-year-old approval of the safe and effective abortion and miscarriage medication, mifepristone. Although expected, the ruling throws into question the FDA’s authority over all medicines and threatens to weaken the country’s premier drug development pipeline, industry leaders and legal experts say.
In a public letter that circulated over the weekend, executives and leaders of the biotechnology and pharmaceutical industries condemned the ruling and called for its reversal along with “appropriate restitution” of the FDA’s authority.
